⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BHVN News
Biohaven Ltd.
Biohaven to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026
prnewswire.com
BHVN
Biohaven Provides Update From Phase 2 Proof-of-Concept Study with BHV-7000 in Major Depressive Disorder
prnewswire.com
BHVN
Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress
prnewswire.com
BHVN
REGN
Migraine Clinical Trial Pipeline Expands as 30+ Companies Driving Innovation in Oncology Therapeutics Space | DelveInsight
globenewswire.com
LUN
LLY
AMGN
NVS
TEVA
ALLER
BHVN
DRREDDY
ABBV
IMPL
ZSAN
AXSM
AEON
IONS
CHRC
AZN
GSK
WSTN
Biohaven Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $200M
prnewswire.com
BHVN
Biohaven Announces Pricing of $175 Million Public Offering of Common Shares
prnewswire.com
BHVN
Biohaven Announces Proposed Public Offering of Common Shares
prnewswire.com
BHVN
Biohaven Reports Third Quarter 2025 Financial Results and Recent Business Developments
prnewswire.com
BHVN
FDA Issues Complete Response Letter for Biohaven's VYGLXIA (troriluzole) New Drug Application for Spinocerebellar Ataxia
prnewswire.com
BHVN
Biohaven Ltd. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before September 12, 2025 to Discuss Your Rights - BHVN
prnewswire.com
BHVN